Table 4

Permanent Study Treatment Discontinuations

Valsartan (n = 185)Placebo (n = 181)Total (n = 366)p Value*
Adverse events18 (9.7%)23 (12.7%)41 (11.2%)0.367
Life-threatening laboratory abnormalities1 (0.5%)1 (0.6%)2 (0.5%)0.988
Hypotension1 (0.5%)1 (0.6%)2 (0.5%)0.988
Other12 (6.5%)20 (11.1%)32 (8.7%)0.122
Total32 (17.3%)45 (24.9%)77 (21.0%)0.076
  • * By chi-square test.

  • Persistent standing systolic blood pressure <80 mm Hg or symptoms of hypotension.